Risk and management of post-operative infectious complications in inflammatory bowel disease: A systematic review

Table 8 Anti-integrin antibodies

Ref.	Year	Patient cohort	Studies comparing VDZ to either anti-TNF or no biologics	Last dose of VDZ	Overall results
Law et al[27]	2018	IBD: UC and CD	5 studies: UC only, retrospective; Retrospective; Retrospective; Post hoc analysis; Retrospective	Within 16 wk; Within 12 wk; Within 12 wk; N/A; Within 4 wk	No significant increase in post-operative infectious complications when compared to anti-TNF treatment or no biologics
Yung et al[28]	2018	IBD: UC and CD	4 studies: UC only, retrospective; CD only, retrospective; Retrospective; Retrospective	16 wk; 12 wk; 12 wk; 4 wk	No significant differences in infectious complications and SSI were noted in the group VDZ vs anti-TNF or no biologics; the results were similar in UC and CD patients
Guo et al[29]	2021	IBD: UC and CD	12 studies	4-16 wk	Decreased risk of overall post-operative infection complications; however, risk of infection at specific sites-SSI, deep SSI increased

CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; SSI: surgical site infection; VDZ: Vedolizumab; TNF: Tumor Necrosis Factor.